You can also read the IBTA e-News June 2020 edition in full online here.
Some of the highlights from this month's round-up:
- The Australian Government has announced that it will invest AUD $3 million in four childhood brain tumour trials.
- Novocure has announced the launch of 'MyLink', a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist.
- A new machine learning algorithm can classify glioma brain tumours from MRI scans into low or high grades with high accuracy, researchers report in the journal IEEE Access.
- A research team has found that tumour necrosis factor (TNF) appears to increase the sensitivity of childhood medulloblastoma tumours to immunotherapy by making tumour cells more visible to the immune system, according to experiments in mice.
- A study published in the Journal of Neuro-Oncology has found in a series of lab experiments that sonodynamic therapy (SDT) has a tumour-killing effect on glioblastoma cells. The approach combines focused ultrasound (FUS) with the "sonosensitizing" drug, 5-aminolevulinic acid hydrochloride (5-ALA).
- Research published in The EMBO Journal has demonstrated how glioblastoma cells exploit surrounding microglia cells, a type of immune cell, to help them evade other elements of the body’s immune system
- The US Food and Drug Administration (FDA) has granted orphan drug designation to berubicin, developed by CNS Pharmaceuticals, for the treatment of patients with malignant gliomas..
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.